|
1. Biologie
|
|
|
|
2. Etiologie
|
|
|
|
2.5 Etiologie - Gènes
|
|
|
|
5. Traitements
|
|
|
New ovarian cancer drugs raise hope — but not for all [STAT]
|
|
|
|
|
|
The
international study enrolled more than 500 women with recurring ovarian
cancer and found the drug “significantly prolonged” the amount of time
before tumors started growing again, necessitating another round of
chemotherapy, though it did not look at whether patients lived longer on
the drug.
|
|
|
|
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
Pazdur to Head New Oncology Center at FDA [RAPS]
|
|
|
|
|
|
The
announcement comes just weeks after a group of 28 cancer groups,
including the nonprofit Friends of Cancer Research (FOCR), sent a letter
to FDA calling for the agency to create such a center to oversee all
oncology products.
|
|
|
|
|
|
|
|
Brexit Creating a Period of Uncertainty for EU, UK Drug and Device Regulators [RAPS]
|
|
|
|
|
|
“At
this point the UK government has not yet initiated the treaty process
(Article 50) for withdrawing from the EU,” Woods said. “We therefore
have no knowledge of the future EU and UK negotiating positions, which
will determine what might be retained of the present medicines and
medical devices regulatory systems. It is probably not helpful to
speculate on the details until the broad outlines have been drawn.”
|
|
|
|
|
|
|
|
|
Top Officials Aim To Reshape The FDA To Prepare For 'Avalanche' Of Cancer Products [Forbes]
|
|
|
|
|
|
Previously,
Pazdur had authority over the pills and antibodies developed by
companies like Roche, Merck and Bristol-Myers Squibb But diagnostic
tests, from firms like Illumina and Foundation Medicine, are likely to
be just as important. And now companies like Novartis , Juno
Therapeutics and Kite Pharmaceuticals are developing genetically
engineered cells that hunt down and kill cancer–products that would be
reviewed by yet another FDA division.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
Is There a Cure for High Drug Prices? [Consumer Reports]
|
|
|
|
|
|
The
cost of prescription drugs for tens of millions of Americans rose $2
billion last year, and all signs point to a continued rise. At stake is
nothing less than the ability of Americans to afford the medicines they
need. Can we stop the madness?
|
|
|
|
|
|
|
5.6 ESMO
|
|
|
|
|
6.1 Observation
|
|
|
Melanoma diagnoses hit 10,000 a year for over 55s [Cancer Research UK]
|
|
|
|
|
|
For
the first time in the UK, more than 10,000 people aged 55 and over were
diagnosed with malignant melanoma - the most dangerous form of skin
cancer - in a single year, according to the latest figures released by
Cancer Research UK. This compares with around 3,100 cases diagnosed in
the UK 20 years ago.
|
|
|
|
|
|
|
Aging Population Is Growing Ranks of Cancer Survivors [AACR]
|
|
|
|
|
|
They
projected U.S. cancer prevalence from 2016 to 2040 by using U.S. Census
Bureau data, and applying the Prevalence Incidence Approach Model. SEER
data linked with Medicare claims were used to estimate comorbidities
commonly experienced in older adults, including health conditions such
as heart disease, lung disease, or diabetes.
|
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
Firsthand Account: The Biden Moonshot Summit [Forbes]
|
|
|
|
|
|
While
it’s hardly news to point out the degree of frustration associated with
the sharing of clinical health data, I was struck by the abiding
pessimism that sharing is going to improve on its own any time soon–that
somehow the problem (seen by almost everyone as fundamentally cultural,
not technical) is going to “work itself out.”
|
|
|
|
|
|
|
|
|
6.6 Publications
|
|
|
|
|
6.9 Controverses
|
|
|
Expertology [In the Pipeline]
|
|
|
|
|
|
What
to do, then, about “Matter for Experts” decisions where the people
affected by them aren’t experts themselves? That’s where the “right to
try” laws fit, I believe, and many other issues as well in a large,
developed country like ours.
|
|
|
|
|
|
|
Will Precision Medicine Improve Public Health? [YouTube]
|
|
|
|
|
|
In
this session, Dr. Muin J. Khoury (Director, Office of Public Health
Genomics, Centers for Disease Control and Prevention) and Dr. Sandro
Galea (Dean & Robert A. Knox Professor, Boston University School of
Public Health) give alternating viewpoints on whether the field of
public health will be accelerated and improved with the new era of
precision medicine.
|
|
|
|